Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARAVIROC: CCR5 Inhibition for Lung Transplant Induction
NCT06853223Phase 2Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Dec 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of maraviroc in primary graft dysfunction (PGD), sponsored by University of California, San Francisco. Started Dec 2025; status: recruiting.
02
Drugs
maraviroc
03
Conditions
primary graft dysfunction (PGD)
Beyond the preview
Go deeper on NCT06853223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06853223.